{"id":"W4387811066","doi":"10.1016/j.annonc.2023.09.2184","title":"1045P Safety and preliminary clinical activity of JNJ-78306358 (JNJ-358), an HLA-G and CD3 bispecific antibody, for the treatment of advanced stage solid tumor","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Reproductive System and Pregnancy","field":"Immunology and Microbiology","cited_by":3,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"Janssen Research and Development; Daiichi Sankyo Europe; CRIS Cancer Foundation; Servier; PharmaMar; European Society for Medical Oncology; Astellas Pharma; Eisai; Chugai Pharmaceutical; Seagen; Genentech; F-star Therapeutics; Sierra Oncology; Pfizer; Incyte; Regeneron Pharmaceuticals; Eli Lilly and Company; AstraZeneca; American Society of Clinical Oncology; Sociedad Española de Oncología Médica; BeiGene; Sanofi; Johns Hopkins University; Amgen; Celgene","keywords":"Medicine; Internal medicine; Gastroenterology; Adverse effect; Cancer; Oncology; Renal cell carcinoma; Response Evaluation Criteria in Solid Tumors; Pharmacodynamics; Progressive disease; Pharmacokinetics; Chemotherapy","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005910725,0.0004045168,0.0004640686,0.0002111424,0.0002857712,0.0004465032,0.0004052391,0.0007584795,0.003376523],"category_scores_gemma":[0.0005802001,0.0001495277,0.0004240092,0.0001722695,0.0003319716,0.0002323372,0.000112275,0.001455933,0.001007382],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004758745,"about_ca_system_score_gemma":0.0006957849,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001638649,"about_ca_topic_score_gemma":0.001395345,"domain_scores_codex":[0.9997801,0.00009052861,0.00001059631,0.00002254994,0.00004130039,0.00005490895],"domain_scores_gemma":[0.9997446,0.00007753489,0.00003914077,0.00002738341,0.00003039754,0.00008098462],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.1156243,0.01871175,0.01119327,0.0006060633,0.0003741278,0.001864594,0.0002649504,0.005474284,0.4322909,0.001331166,0.01452289,0.3977416],"study_design_scores_gemma":[0.03924493,0.6099733,0.09069111,0.0001402382,0.0007067753,0.007623469,0.0001622333,0.00942973,0.1775836,0.0009975352,0.06336804,0.00007895318],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9750617,0.003580236,0.002476216,0.0007762478,0.0001578885,0.0004439878,0.001739657,0.0002832839,0.01548082],"genre_scores_gemma":[0.9916285,0.0008969922,0.0007521379,0.0003955294,0.00006702268,0.0001273227,0.001961967,0.00003484762,0.004135609],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003376523,"threshold_uncertainty_score":0.01129556,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1326605395598053,"score_gpt":0.455820497147672,"score_spread":0.3231599575878668,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}